Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GVK BIO To Acquire Aragen Bioscience | Contract Pharma

What are you searching for?

Sign in
Breaking News

GVK BIO To Acquire Aragen Bioscience

Adds biologics expertise and significant U.S. presence

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

GVK BIO has entered an agreement to acquire Aragen Bioscience, Inc., a privately held U.S. based, preclinical CRO specializing in biologics services. GVK BIO is small molecule service provider in Asia. The acquisition expands GVK BIO’s service offering to a broader client base and provides expertise in biologics services, as well as a significant U.S. presence. Financial terms were not disclosed.
 
“As an increasing number of biotech and pharmaceutical companies focus on protein based therapeutics and biosimilars, the acquisition of Aragen Bioscience will strategically enhance GVK BIO’s ability to offer high quality R&D services to the industry from a seamless integrated platform,” said Mr. D. S. Brar, chairman, GVK BIO.
 
“Aragen’s scientific excellence and expertise in large-molecule R&D services combined with GVK BIO’s scale, resources, and global reach will create significant synergies for both companies,” said Rick Srigley, president and chief executive officer, Aragen Bioscience.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics